SEARCH

Search results for: PPMI

Parkinson’s Progression Markers Initiative (PPMI)

About PPMI The Parkinson’s Progression Markers Initiative (PPMI) is an observational research study to identify biomarkers of Parkinson’s disease (PD) progression. A biomarker is a substance or characteristic in our bodies that is associated with the presence of disease, or that changes over tim...

Visit Page

PPMI Study Update: Early Signs and Some Potential Markers

The landmark Parkinson’s Progression Markers Initiative (PPMI) study aims to better define and measure Parkinson’s disease so scientists can find new ways to treat it. Now following nearly 1,400 participants at 33 clinical sites around the world, PPMI collects data and biosamples over at least f...

Visit Page

PPMI Study Reaches Important Milestone

The Parkinson’s Progression Markers Initiative (PPMI) has reached an important milestone: the study completed enrollment. We have now met the ambitious goal we set back in 2010 of enrolling 1,400 participants, including 600 with rare genetic mutations. PPMI is The Michael J. Fox Foundation’s lan...

Visit Page

Marc Joins PPMI Study to Support his Wife Karen

Sunday Night Australia taped exclusive interviews with friends of the Foundation last month, including Parkinson’s Progression Markers Initiative (PPMI) control participant Marc Jaffe, his wife Karen and Dr. Ken Marek, the study’s principal investigator. PPMI is The Michael J. Fox Foundation’s...

Visit Page

PPMI Study Shows Brain Changes Linked to Parkinson’s Progression

Two recent papers point to potential Parkinson’s biomarkers after analysis of data from The Michael J. Fox Foundation’s (MJFF) Parkinson’s Progression Markers Initiative (PPMI). PPMI is a landmark study following more than 1,500 volunteers at 33 clinical sites around the world, and provides i...

Visit Page

Important PPMI Results Highlighted in USA Today

The first major study results from the Parkinson’s Progression Markers Initiative (PPMI) are highlighted in today’s edition of USA Today. The study, which was published in the journal JAMA Neurology, studied the cerebrospinal fluid of people with Parkinson’s disease (PD) as compared with cont...

Visit Page

Is Parkinson’s Disease Genetic? Maybe

Everyone in the Parkinson’s disease (PD) community likely has heard this question and asked it themselves. We say that PD is rarely caused by genetics, but what does that mean for those living with the disease today, their children and family? There remain many more questions surrounding the gene...

Visit Page

Caffeine a Potential Marker for Parkinson’s

Millions of people reach for a caffeinated beverage each morning to jumpstart the day. Now, early research indicates that the stimulant that gets people moving also might help diagnose Parkinson’s disease (PD). A recent study published in Neurologyfound that people with Parkinson’s had signif...

Visit Page

Common Link Across Different Causes of Parkinson’s

Parkinson’s is a variable disease — different in age of onset, experience of symptoms and cause — but a new study points to a potential common link. “Finding a common mechanism behind different suspected causes of Parkinson’s suggests that there might also be a common means to measure, tre...

Visit Page

Parkinson’s Research Conference Spotlights Advances

On October 30, more than 300 leaders in Parkinson’s disease (PD) research and business development gathered in NYC for The Michael J. Fox Foundation’s 11th Annual Parkinson’s Disease Therapeutics Conference. The event featured the latest in Parkinson’s drug development and innovative researc...

Visit Page

Our MJFF Partnership

In August 2011, Shake It Up Australia Foundation established a collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to leverage Parkinson’s drug development expertise In Australia.

Visit Page

A Family Affair: The Genetics of Parkinson’s

The below post is written by Genia Brin, mother of internet entrepreneur and Google Co-Founder Sergey Brin. Care of the Michael J Fox Foundation, Genia looks into how her family went about finding out if they were impacted by a genetic mutation that plays a role in causing Parkinson’s.  See how h...

Visit Page

Neurologist Profile: Professor Dominic Rowe

Professor Dominic Rowe, the man at the center of some of the World’s best Parkinson’s research. Here’s what inspires him in his search for change: What Drives Your Commitment to find a cure for Parkinson’s? From early in my training in neurology, I have wanted to know what causes Parkinson...

Visit Page

Shake It Up Hero – Ian Read

Ian Read is our Hero for his participation in Parkinson’s Clinical trails here in Australia. People like Ian play a HUGE role in finding the cure for Parkinson’s disease and for that we will always be thankful. Did you know that fewer than 10% of Parkinson’s patients ever take part in trials, ...

Visit Page

Study’s Measure Parkinson’s Progression

Two recent papers outline the progression of Parkinson’s disease (PD) movement or motor symptoms in distinct study populations. While these findings do not provide an absolute picture of how one person will progress with PD, the results may help researchers design smaller, faster and less expensiv...

Visit Page

Trial Testing Drug in People with Parkinson’s and a GBA Mutation

Sanofi Genzyme has started a clinical trial for a drug targeting cellular dysfunction seen in people with Parkinson’s disease (PD) and a GBA mutation. This study is a major step for PD research as it is the first drug trial where one’s genetic information determines eligibility and is testing...

Visit Page

Podcast – Latest in Parkinson’s Research

Earlier this month three members of The Michael J. Fox Foundation staff sat with Contributing Editor Dave Iverson to discuss the latest findings and research to better define, measure and treat Parkinson’s disease. Listen to the Podcast https://www.michaeljfox.org/sites/default/files/audio/podcas...

Visit Page

Blood Test May Help Confirm a Parkinson’s Diagnosis

Parkinson’s disease (PD) is a complex and varied disorder with many different potential motor and non-motor symptoms. Early on, it can sometimes be difficult to determine whether symptoms are caused by Parkinson’s or an atypical parkinsonism, a condition that shares some of the motor symptoms (t...

Visit Page

Researchers Looking to Improve Diagnosis of Parkinson’s

No objective measurement — or biomarker — currently exists to diagnose Parkinson’s disease (PD). Instead, doctors must rely on a person’s medical history and physical examination to recognize the disease. This can sometimes result in missed or incorrect diagnoses, so significant research e...

Visit Page

Podcast: 2018 Parkinson’s Research Year in Review and Look Ahead

Parkinson’s research continues to advance at a rapid pace. Led by moderator Soania Mathur, MD, co-chair of The Michael J. Fox Foundation’s Patient Council, panelists Andrew Siderowf, MD, director, Parkinson’s Disease and Movement Disorders Center and Todd Sherer, PhD, MJFF CEO unpack milestone...

Visit Page

Another Leap Forward for LRKK2 Development

Denali Therapeutics — a San Francisco biotech that launched last year focused on neurodegenerative diseases including Parkinson’s — recently announced it has licensed LRRK2 inhibitor compounds from Genentech. These drug candidates may address the dysfunction seen with LRRK2 mutations, the g...

Visit Page

Stem Cells Safe in Pre-Clinical Parkinson’s Disease Study

A new stem cell study, published in the journal Nature, builds on the potential for this therapy in Parkinson’s, but it’s still early days and much work remains to be done. A team of researchers demonstrated that human induced pluripotent stem cells (iPSCs) — “man-made” stem cells created...

Visit Page

Study Finds Depression Linked to Increased Risk of Parkinson’s

Depression may be an early indicator of Parkinson’s disease (PD) risk, reports study findings published in the journal Neurology last week. Investigators looked at data from more than 20,000 people with and without depression from over 10 years culled from the Taiwan National Health Insurance Re...

Visit Page

Ask the MD: Smell Loss in Coronavirus and Parkinson’s

How do we smell? Tiny odour molecules — of cookies baking in the oven, laundry that needs to be cleaned, or rosemary growing in the garden — travel in the air through the nose to the smell, or olfactory, nerve. These molecules bind to receptors on the olfactory nerve, which transmits information...

Visit Page

SIGN UP FOR EMAIL UPDATES

GET PARKINSON'S RESEARCH NEWS, FOUNDATION UPDATES, INVITATIONS TO EVENTS AND MORE.